Download PDF
Transfusionsmedizin 2014; 4(2): 88-102
DOI: 10.1055/s-0033-1357912
CME-Fortbildung
Georg Thieme Verlag KG Stuttgart · New York

Immunthrombozytopenie: Pathophysiologie, Diagnostik, Therapie

V. Kiefel
Further Information

Publication History

Publication Date:
14 May 2014 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Unter dem Begriff Immunthrombozytopenie (ITP) wird eine Gruppe von Erkrankungen zusammengefasst, bei denen aus unbekannten Gründen die immunologische Toleranz gegen die Thrombozyten (zeitweilig) verloren geht. Im Kindesalter wird die akute ITP häufig durch virale Infekte oder Impfungen getriggert, der Beginn der chronischen ITP wird häufig nicht wahrgenommen und die Erkrankung nimmt oft einen fluktuierenden Verlauf mit schwankenden Thrombozytenzahlen. Die primäre ITP tritt ohne (immunologische) Grund- oder Begleiterkrankungen auf, sekundäre Autoimmunthrombozytopenien werden im Zusammenhang mit SLE (systemischer Lupus erythematodes), CLL (chronische lymphatische Leukämie), Tumorerkrankungen und Infektionen beobachtet. Therapeutische Interventionen sind häufig prophylaktisch begründet, sie sollen spontane Blutungen oder Blutungen bei geplanten operativen oder diagnostischen Eingriffen vermeiden. Besonders gefürchtet sind die bei thrombozytopenischen Patienten glücklicherweise selten auftretenden spontanen zerebralen Blutungen. Neben Kortikosteroiden, immunsuppressiven Substanzen, hoch dosiertem intravenösem IgG (Immunglobulin G) spielen zunehmend die kürzlich zugelassenen Thrombopoetinrezeptoragonisten (TRA) eine Rolle bei therapierefraktären ITP-Patienten. Obwohl die Erkrankung schon lange bekannt ist und die immunologische Genese vor mehr als 60 Jahren beschrieben wurde, werden viele Aspekte der Pathogenese der ITP auch heute noch nicht völlig verstanden.

Key words

Thrombozytopenie - ITP - Immunthrombozytopenie - Blutung - Petechien - zerebrale Blutung - thrombozytäre Autoantikörper - MAIPA
 

  • Literatur

  • 1 Rodeghiero F, Stasi R, Gernsheimer T et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113: 2386-2393
    CrossrefPubMedGoogle Scholar
  • 2 Stasi R, Newland AC. ITP: a historical perspective. Br J Haematol 2011; 153: 437-450
    CrossrefPubMedGoogle Scholar
  • 3 Harrington WJ, Minnich V, Hollingsworth JW et al. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951; 38: 1-10
    PubMedGoogle Scholar
  • 4 Shulman NR, Marder VJ, Weinrach RS. Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies. Ann NY Acad Sci 1965; 124: 499-542
    PubMedGoogle Scholar
  • 5 Imbach P, Barandun S, dʼApuzzo V et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; i: 1228-1231
    PubMedGoogle Scholar
  • 6 Lewis DC, Meyers KM. Studies of platelet-bound and serum platelet-bindable immunoglobulins in dogs with idiopathic thrombocytopenic purpura. Exp Hematol 1996; 24: 696-701
    PubMedGoogle Scholar
  • 7 Nakamura RK, Tompkins E, Bianco D. Therapeutic options for immune-mediated thrombocytopenia. J Vet Emerg Crit Care 2012; 22: 59-72
    PubMedGoogle Scholar
  • 8 Aster RH, Jandl JH. Platelet sequestration in man. II. Immunological and clinical studies. J Clin Invest 1964; 43: 856-869
    CrossrefPubMedGoogle Scholar
  • 9 Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood 1985; 66: 1105-1109
    PubMedGoogle Scholar
  • 10 Ballem PJ, Segal GM, Stratton JR et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987; 80: 33-40
    CrossrefPubMedGoogle Scholar
  • 11 Nishimoto T, Kuwana M. CD4+CD25+Foxp3+ regulatory T cells in the pathophysiology of immune thrombocytopenia. Semin Hematol 2013; 50 (Suppl. 01) S43-S49
    CrossrefPubMedGoogle Scholar
  • 12 Zhao C, Li X, Zhang F et al. Increased cytotoxic T-lymphocyte-mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies. Haematologica 2008; 93: 1428-1430
    CrossrefPubMedGoogle Scholar
  • 13 von Gunten S, Wehrli M, Simon HU. Cell death in immune thrombocytopenia: novel insights and perspectives. Semin Hematol 2013; 50 (Suppl. 01) S109-S115
    CrossrefPubMedGoogle Scholar
  • 14 Baldini M. Idiopathic thrombocytopenic purpura. N Engl J Med 1966; 274: 1245-1251
    CrossrefPubMedGoogle Scholar
  • 15 Kuhne T, Buchanan GR, Zimmerman S et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr 2003; 143: 605-608
    CrossrefPubMedGoogle Scholar
  • 16 Liebman HA, Cines DB, Bussel JB. Immune Thrombocytopenia and Posttransfusion Purpura. In: Marder VJ, Aird WC, Bennett JS, Schulman S, White GC, Hrsg. Hemostasis and Thrombosis. 6. Aufl. Philadelphia: Wolters Kluwer, Lippincott Williams and Wilkins; 2013: 763-775
    Google Scholar
  • 17 Psaila B, Petrovic A, Page LK et al. Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood 2009; 114: 4777-4783
    CrossrefPubMedGoogle Scholar
  • 18 Baer VL, Lambert DK, Henry E et al. Severe thrombocytopenia in the NICU. Pediatrics 2009; 124: e1095-e1100
    CrossrefPubMedGoogle Scholar
  • 19 Balduini CL, Savoia A, Seri M. Inherited thrombocytopenias frequently diagnosed in adults. J Thromb Haemost 2013; 11: 1006-1019
    CrossrefPubMedGoogle Scholar
  • 20 Schuff-Werner P, Steiner M, Fenger S et al. Effective estimation of correct platelet counts in pseudothrombocytopenia using an alternative anticoagulant based on magnesium salt. Br J Haematol 2013; 162: 684-692
    CrossrefPubMedGoogle Scholar
  • 21 Provan D, Stasi R, Newland AC et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168-186
    CrossrefPubMedGoogle Scholar
  • 22 von dem Borne AEGK, Helmerhorst FM, van Leeuwen EF et al. Autoimmune thrombocytopenia: detection of platelet autoantibodies with the suspension immunofluorescence test. Br J Haematol 1980; 45: 319-327
    CrossrefPubMedGoogle Scholar
  • 23 Dixon R, Rosse WF, Ebbert L. Quantitative determination of antibody in idiopathic thrombocytopenic purpura. Correlation of serum and platelet-bound antibody with clinical response. N Engl J Med 1975; 292: 230-236
    CrossrefPubMedGoogle Scholar
  • 24 Kiefel V, Santoso S, Weisheit M et al. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet reactive antibodies. Blood 1987; 70: 1722-1726
    PubMedGoogle Scholar
  • 25 Kiefel V. The MAIPA assay and its applications in immunohematology. Transfus Med 1992; 2: 181-188
    CrossrefPubMedGoogle Scholar
  • 26 Kiefel V, Santoso S, Kaufmann E et al. Autoantibodies against platelet glycoprotein Ib/IX: a frequent finding in autoimmune thrombocytopenic purpura. Br J Haematol 1991; 79: 256-262
    CrossrefPubMedGoogle Scholar
  • 27 Kiefel V, Freitag E, Kroll H et al. Platelet autoantibodies (IgG, IgM, IgA) against glycoproteins IIb/IIIa and Ib/IX in patients with thrombocytopenia. Ann Hematol 1996; 72: 280-285
    CrossrefPubMedGoogle Scholar
  • 28 Von Stein S, Müller T, Nienaber C et al. Antibodies against abciximab-coated platelets interfere with platelet autoantibody detection and react with the cleavage site of Fab fragments [abstract]. Hämostaseologie 2006; 26: A17
    PubMedGoogle Scholar
  • 29 Matzdorff A, Giagounidis A, Greinacher A et al. Diagnostik und Therapie der Immunthrombozytopenie. Empfehlungen einer gemeinsamen Expertengruppe der DGHO, DGTI und GTH. Onkologie 2010; 33 (Suppl. 03) 2-20
    PubMedGoogle Scholar
  • 30 Matzdorff A, Wolfgang Eberl W, Giagounidis A et al. Immunthrombozytopenie (ITP), Onkopedia-Leitlinie (2013). Im Internet: http://www.dgho-onkopedia.de/de/onkopedia/leitlinien/immunthrombozytopenie-itp Stand: November 2013
    PubMedGoogle Scholar
  • 31 Dickerhoff R, Eberl W. Leitlinie Immunthrombozytopenie (ITP) im Kindes- und Jugendalter (AWMF) (2011). Im Internet: http://www.awmf.org/leitlinien/detail/ll/086-001.html Stand: 01.08.2011
    PubMedGoogle Scholar
  • 32 Neunert C, Lim W, Crowther M et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117: 4190-4207
    CrossrefPubMedGoogle Scholar
  • 33 Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214
    CrossrefPubMedGoogle Scholar
  • 34 Heddle NM, Cook RJ, Tinmouth A et al. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009; 113: 1564-1573
    CrossrefPubMedGoogle Scholar
  • 35 Salama A, Kiesewetter H, Kalus U et al. Massive platelet transfusion is a rapidly effective emergency treatment in patients with refractory autoimmune thrombocytopenia. Thromb Haemost 2008; 100: 762-765
    PubMedGoogle Scholar
  • 36 Davies JM, Lewis MP, Wimperis J et al. Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British Committee for Standards in Haematology by a working party of the Haemato-Oncology task force. Br J Haematol 2011; 155: 308-317
    CrossrefPubMedGoogle Scholar
  • 37 Kojouri K, Vesely SK, Terrell DR et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104: 2623-2634
    CrossrefPubMedGoogle Scholar
  • 38 Meyer O, Kiesewetter H, Hermsen M et al. Replacement of intravenous administration of anti-D by subcutaneous administration in patients with autoimmune thrombocytopenia. Pediatr Blood Cancer 2006; 47: 721-722
    CrossrefPubMedGoogle Scholar
  • 39 Matzdorff A, Beer JH. Immune thrombocytopenia patients requiring anticoagulation–maneuvering between Scylla and Charybdis. Semin Hematol 2013; 50 (Suppl. 01) S83-S88
    CrossrefPubMedGoogle Scholar
  • 40 Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med 1993; 329: 1463-1466
    CrossrefPubMedGoogle Scholar
  • 41 Gill KK, Kelton JG. Management of idiopathic thrombocytopenic purpura in pregnancy. Semin Hematol 2000; 37: 275-289
    CrossrefPubMedGoogle Scholar
  • 42 Christiaens GC, Nieuwenhuis HK, Bussel JB. Comparison of platelet counts in first and second newborns of mothers with immune thrombocytopenic purpura. Obstet Gynecol 1997; 90: 546-552
    CrossrefPubMedGoogle Scholar
  • 43 Gandemer V, Kaplan C, Quelvennec E et al. Pregnancy-associated autoimmune neonatal thrombocytopenia: role of maternal HLA genotype. Br J Haematol 1999; 104: 878-885
    CrossrefPubMedGoogle Scholar
  • 44 Valat AS, Caulier MT, Devos P et al. Relationships between severe neonatal thrombocytopenia and maternal characteristics in pregnancies associated with autoimmune thrombocytopenia. Br J Haematol 1998; 103: 397-401
    CrossrefPubMedGoogle Scholar
  • 45 Yamada H, Kato EH, Kishida T et al. Risk factors for neonatal thrombocytopenia in pregnancy complicated by idiopathic thrombocytopenic purpura. Ann Hematol 1998; 76: 211-214
    CrossrefPubMedGoogle Scholar
  • 46 Samuels P, Bussel JB, Braitman LE et al. Estimation of the risk of thrombocytopenia in the offspring of pregnant women with presumed immune thrombocytopenic purpura. N Engl J Med 1990; 323: 229-235
    CrossrefPubMedGoogle Scholar
  • 47 Webert KE, Mittal R, Sigouin C et al. A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura. Blood 2003; 102: 4306-4311
    CrossrefPubMedGoogle Scholar
  • 48 Gernsheimer TB. Thrombocytopenia in pregnancy: is this immune thrombocytopenia or…?. Hematology Am Soc Hematol Educ Program 2012; 2012: 198-202
    PubMedGoogle Scholar
  • 49 von dem Borne AE, Pegels JG, van der Stadt RJ et al. Thrombocytopenia associated with gold therapy: a drug-induced autoimmune disease?. Br J Haematol 1986; 63: 509-516
    CrossrefPubMedGoogle Scholar
  • 50 Garner SF, Campbell K, Metcalfe P et al. Glycoprotein V: the predominant target antigen in gold-induced autoimmune thrombocytopenia. Blood 2002; 100: 344-346
    CrossrefPubMedGoogle Scholar
  • 51 Aster RH. Can drugs cause autoimmune thrombocytopenic purpura?. Semin Hematol 2000; 37: 229-238
    CrossrefPubMedGoogle Scholar
  • 52 Tomer A, Schreiber AD, McMillan R et al. Menstrual cyclic thrombocytopenia. Br J Haematol 1989; 71: 519-524
    CrossrefPubMedGoogle Scholar
  • 53 Menitove JE, Pereira J, Hoffman R et al. Cyclic thrombocytopenia of apparent autoimmune etiology. Blood 1989; 73: 1561-1569
    PubMedGoogle Scholar
  • 54 Kosugi S, Tomiyama Y, Shiraga M et al. Cyclic thrombocytopenia associated with IgM anti-GPIIb-IIIa autoantibodies. Br J Haematol 1994; 88: 809-815
    CrossrefPubMedGoogle Scholar
  • 55 Mueller-Eckhardt C, Kiefel V. High-dose IgG for post-transfusion purpura-revisited. Blut 1988; 57: 163-167
    CrossrefPubMedGoogle Scholar
  • 56 Niessner H, Clemetson KJ, Panzer S et al. Acquired thrombasthenia due to GP II b/III a-specific autoantibodies. Blood 1986; 68: 571-576
    PubMedGoogle Scholar
  • 57 Kubota T, Tanoue K, Murohashi I et al. Autoantibody against platelet glycoprotein II b/III a in a patient with non Hodgkinʼs lymphoma. Thromb Res 1989; 53: 379-386
    CrossrefPubMedGoogle Scholar
  • 58 McMillan R, Bowditch RD, Tani P et al. A non-thrombocytopenic bleeding disorder due to an IgG4-kappa anti-GPIIb/IIIa autoantibody. Br J Haematol 1996; 95: 747-749
    CrossrefPubMedGoogle Scholar
  • 59 Tholouli E, Hay CR, OʼGorman P et al. Acquired Glanzmannʼs thrombasthenia without thrombocytopenia: a severe acquired autoimmune bleeding disorder. Br J Haematol 2004; 127: 209-213
    CrossrefPubMedGoogle Scholar
  • 60 Porcelijn L, Huiskes E, Maatman R et al. Acquired Glanzmannʼs thrombasthenia caused by glycoprotein IIb/IIIa autoantibodies of the immunoglobulin G1 (IgG1), IgG2 or IgG4 subclass: a study in six cases. Vox Sang 2008; 95: 324-330
    CrossrefPubMedGoogle Scholar